Guilhaume Debroas
Head of Corporate Development Maat Pharma
Seminars
Wednesday 28th January 2026
MaaT013: The First Phase 3 Trial for a Microbiome Therapy in Hemato-Oncology
9:00 am
- Presentation of the positive topline results from the pivotal Phase 3 ARES trial evaluating MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD), marking a milestone as the first global Phase 3 trial of a microbiome-based therapy in hemato-oncology.
- Analysis of the ARES trial outcomes, highlighting MaaT013’s unprecedented efficacy as a third-line treatment for GI-aGvHD and its potential to reshape therapeutic approaches in this high-need patient population.
- Potential of microbiome-based therapies in hemato-oncology
